Literature DB >> 9023127

Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency.

M W Linder1, R A Prough, R Valdes.   

Abstract

Pharmacogenetics is the study of the linkage between an individual's genotype and that individual's ability to metabolize a foreign compound. Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug. Phenotypes exhibiting poor and ultraextensive metabolism result from genetic variance (polymorphism) of enzymes involved in metabolism. Thus, in pharmacogenetic studies one applies genotyping of polymorphic alleles encoding drug-metabolizing enzymes to the identification of an individual's drug metabolism phenotype. This knowledge, when applied to dosing or drug selection, can avoid adverse reactions or therapeutic failure and thus enhance therapeutic efficiency. More than 25 commonly prescribed medicines are metabolized by the cytochrome P-4502D6 (CYP2D6) isoenzyme, and polymorphism of the CYP2D6 gene affects the therapeutic management of up to 17% of individuals in some ethnic groups. In this review, we summarize and update information concerning drug-metabolizing genotypes with emphasis on CYP2D6 genotyping techniques that can be applied by the clinical laboratory for linking human genetics to therapeutic management.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9023127

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  18 in total

Review 1.  Therapeutic drug monitoring of psychotropic medications.

Authors:  P B Mitchell
Journal:  Br J Clin Pharmacol       Date:  2000-04       Impact factor: 4.335

2.  Genetic polymorphism of CYP2D6 in a keralite (South India) population.

Authors:  B K Abraham; C Adithan; C H Shashindran; S Vasu; N A Alekutty
Journal:  Br J Clin Pharmacol       Date:  2000-03       Impact factor: 4.335

Review 3.  Racial and ethnic differences in response to medicines: towards individualized pharmaceutical treatment.

Authors:  Valentine J Burroughs; Randall W Maxey; Richard A Levy
Journal:  J Natl Med Assoc       Date:  2002-10       Impact factor: 1.798

Review 4.  Pharmacogenetics: a tool for individualizing antineoplastic therapy.

Authors:  F Innocenti; L Iyer; M J Ratain
Journal:  Clin Pharmacokinet       Date:  2000-11       Impact factor: 6.447

5.  CYP2D6 genotyping as an alternative to phenotyping for determination of metabolic status in a clinical trial setting.

Authors:  S McElroy; C Sachse; J Brockmoller; J Richmond; M Lira; D Friedman; I Roots; B M Silber; P M Milos
Journal:  AAPS PharmSci       Date:  2000

Review 6.  How may anticancer chemotherapy with fluorouracil be individualised?

Authors:  Su-arpa Ploylearmsaeng; Uwe Fuhr; Alexander Jetter
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

7.  Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults.

Authors:  Erin A Kolbrich; Robert S Goodwin; David A Gorelick; Robert J Hayes; Elliot A Stein; Marilyn A Huestis
Journal:  Ther Drug Monit       Date:  2008-06       Impact factor: 3.681

8.  Identification of CYP2D6 alleles by single nucleotide polymorphism analysis using pyrosequencing.

Authors:  Anna-Lena Zackrisson; Bertil Lindblom
Journal:  Eur J Clin Pharmacol       Date:  2003-09-06       Impact factor: 2.953

9.  Interactive modeling for ongoing utility of pharmacogenetic diagnostic testing: application for warfarin therapy.

Authors:  Mark W Linder; Marjorie Bon Homme; Kristen K Reynolds; Brian F Gage; Charles Eby; Natalia Silvestrov; Roland Valdes
Journal:  Clin Chem       Date:  2009-08-13       Impact factor: 8.327

10.  Influence of CYP2D6 polymorphisms on symptomatology and side-effects of patients with schizophrenia in Malaysia.

Authors:  Zalina Zahari; Mohd Razali Salleh; Lay Kek Teh; Rusli Ismail
Journal:  Malays J Med Sci       Date:  2009-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.